Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravagalimab induction study in moderate to severe ulcerative colitis after prior therapy failure
NL-OMON49261Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ravagalimab in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoint: Endoscopic improvement at Week 8. Started Nov 2020; status: completed.
02
Drugs
ravagalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON49261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49261.